Breadcrumb

  1. Partner with Santen
  2. Current partnerships

Current partnerships

Home

Pharmaceutical firms

Universities

Research institutes

Manufacturers in other industries

Commercial alliances

Commercial alliances are also very important to us. We look for network-based drug development opportunities, including in-licensing of compounds from external sources to strengthen our pipeline. We also collaborate with commercial partners to investigate and develop new, specialist products. Currently, we have promising pipeline products in joint development with companies specialising in stem cell innovation and AI-based drug discovery.

Globally, we have established commercial relationships with numerous pharmaceutical brands and organisations.

NTC: Co-development project 

Bacterial resistance is one of the main concerns of the 21st century regardless of the therapeutic area. Given that the innovation process for ophthalmic anti-infectives remained stagnant for more than a decade, Santen and NTC entered into this co-development with the intention to develop an alternative option to existing standard of care treatment for post-cataract management and to raise the awareness about bacterial resistance in ophthalmology.

OFF Italia: Distribution/licence agreement for OTC dry eye 

Santen and OFF decided to join forces in co-developing and offering to its customers new treatment options, especially in the field of dry eye, with the intention to leverage sustainably the quality of life for those suffering from dry eye disease. The arrangement foresees a tight cooperation to internationalise a selection of OFF’s brands and jointly develop improvements especially in the field of dry eye. 

Jean-Sébastien Garrigue, Vice President of R&D, EMEA

“We ensure that we address unmet medical needs and achieve faster access for patients to treatments by working closely with partner companies, research institutes and academia.”

Jean-Sébastien Garrigue, Vice President of R&D, EMEA 

Research partnerships

Partnerships are a crucial component of our R&D activities. They enable us to conduct broader, multidisciplinary work so we can better develop innovative therapeutics and technologies to answer current and future unmet patient needs in ophthalmology. Our partnership approach brings together Santen’s asset portfolio and longstanding drug development programme with our research partners’ novel technologies and translational research capabilities.

University of Helsinki, Finland

We have a decades-long research partnership with the Centre for Drug Research (CDR) at the University of Helsinki. This multidisciplinary research group explores pharmaceutical sciences, molecular and cell biology, materials science, bio-organic and physical chemistry, and molecular modelling. Santen researchers are seconded to the research teams. Over the years we have attracted around €1m of outside investment in CDR research projects.

The CDR is headed by Professor Arturo Urtti, one of the world’s leading experts in the field of ophthalmic drug delivery and also a member of Santen’s Drug Delivery System (DDS) advisory board. 

UCL Institute of Ophthalmology and SenSyT, London 

Santen is currently funding eight full time PhD studentships at UCL (University College London) Institute of Ophthalmology (IoO) to study the biology and pathology of eye diseases, including glaucoma, Usher syndrome and diabetic retinopathy. The aim is to develop new methods of diagnosis and treatment for these blinding diseases.

UCL’s Institute of Ophthalmology (IoO) is a world leader in studies of vision and eye diseases. The institute has at least 45 principal investigators and collaborates closely with the famous Moorfields Eye Hospital, London, UK. The Institute is the oldest and largest centre for ophthalmic treatment, teaching and research in the world.

SenSyT (Sensory Systems, Technologies and Therapies) is a multi-disciplinary research network at UCL, committed to advancing basic and translational research to tackle the scientific and biomedical challenges of human sensory health. 

The UCL IoO-Santen PhD Studentship program and other collaborative research at the institute is managed by the Head of the Santen Global Alliances and External Research (GAER) department, Dr. Naj Sharif, PhD, FARVO, FBPhS, Vice President, Santen Inc USA (Emeryville, CA). The Santen GAER Team has also been involved in establishing and conducting collaborative ocular research directed at many eye diseases including at the world-renowned Singapore Eye Research Institute (SERI), at the LV Prasad Eye Research Institute in India, Liverpool University, and partner companies such as Boehringer Ingelheim and twoXAR.

Singapore Eye Research Institute (SERI)

In March 2017 we launched a strategic five-year collaboration with SERI to develop new technologies and novel treatment modalities for ophthalmic diseases and disorders. Santen and the Singapore government jointly invested SGD 37 million (equivalent to €23.5 million) in the programme, with the aim of establishing a robust pipeline of ophthalmology products that will benefit patients globally. Glaucoma, diabetic retinopathy, ocular infections and myopia are the team’s focus domains.

A Santen-SERI joint laboratory is located in the Academia building on the SingHealth campus at Outram Park, Singapore. Scientists from Santen and SERI work together on new product development. Santen’s team includes local hires and experienced scientists from Japan and elsewhere. They work with scientists and clinicians across the research community in Singapore and the Asian region. The Santen-SERI joint Lab is managed by Masaaki Kageyama, PhD, who is another key member of the GAER department.

Santen ventures

In early 2015 established a venture arm and since then co-funds early-stage innovation in ophthalmology. Santen’s interest is to syndicate with lead investors and to assume an observing role to enable free innovation, guiding itself with its sound industrial expertise. To date, Santen has invested in more than half a dozen start-ups and companies. Sweet spot investment targets are entities developing pharmaceuticals, gene therapy, cell therapy, therapeutic devices, drug delivery technologies, biomarkers and diagnostics.